Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Arcus Biosciences, Inc. (NYSE:RCUS) has been given an average rating of “Moderate Buy” by the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $29.3333.

Several research analysts recently weighed in on the company. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research report on Monday, December 15th. Bank of America boosted their price objective on shares of Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a research report on Friday, November 28th. Wells Fargo & Company set a $23.00 target price on shares of Arcus Biosciences and gave the stock an “equal weight” rating in a research report on Thursday, February 12th. The Goldman Sachs Group upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $16.00 to $28.00 in a report on Monday, January 12th. Finally, Truist Financial set a $30.00 price objective on Arcus Biosciences in a research report on Friday, December 12th.

Arcus Biosciences Trading Up 4.2%

NYSE:RCUS opened at $20.36 on Friday. Arcus Biosciences has a 1 year low of $6.50 and a 1 year high of $26.40. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -6.17 and a beta of 0.84. The business has a fifty day moving average of $21.57 and a 200-day moving average of $18.44.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.22. The company had revenue of $33.00 million during the quarter, compared to the consensus estimate of $24.94 million. Arcus Biosciences had a negative return on equity of 69.86% and a negative net margin of 142.91%.The company’s quarterly revenue was down 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.03) EPS. Equities analysts predict that Arcus Biosciences will post -3.15 earnings per share for the current year.

Insiders Place Their Bets

In related news, General Counsel Carolyn C. Tang sold 6,810 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $22.16, for a total transaction of $150,909.60. Following the transaction, the general counsel owned 124,734 shares of the company’s stock, valued at approximately $2,764,105.44. This trade represents a 5.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Alexander Azoy sold 4,343 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $22.25, for a total transaction of $96,631.75. Following the completion of the sale, the chief accounting officer directly owned 18,531 shares of the company’s stock, valued at $412,314.75. This represents a 18.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 263,987 shares of company stock worth $6,025,620 in the last quarter. Corporate insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Hantz Financial Services Inc. increased its position in Arcus Biosciences by 121.9% during the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after acquiring an additional 881 shares during the period. T. Rowe Price Investment Management Inc. bought a new position in shares of Arcus Biosciences during the 4th quarter worth about $39,000. GAMMA Investing LLC grew its position in Arcus Biosciences by 59.1% during the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after buying an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after acquiring an additional 2,845 shares in the last quarter. Finally, Abich Financial Wealth Management LLC bought a new stake in shares of Arcus Biosciences in the 3rd quarter worth approximately $69,000. 92.89% of the stock is owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.